MediWound, a biotech developing treatments for severe burns and other hard-to-heal wounds, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Yavne, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol MDWD. MediWound initially filed confidentially on December 23, 2013. Credit Suisse, Jefferies, and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
